nhf_4c      mer        10th annynoanny ie logo_large
Post-Activity Survey and Evaluation
ManagedCareHemo.com Presents
Hemophilia Clinical Updates and Cost Management Solutions

March 25, 2019
QP
In an effort to better determine the overall effectiveness of continuing education activities, we are conducting a brief survey. Listed below are questions for which we would like your responses. All information obtained will be used and reported in aggregate only, without individual attribution. Thank you for your participation.

If you have any questions please contact us at info@impactedu.net.

*All questions are required.
Q1.1 Now that you have participated in this activity, how confident are you in your ability to distinguish the treatment of hemophilia from the treatment of hemophilia with an inhibitor?
 
Q1.2 What level of factor activity is observed in patients classified as having severe hemophilia?
 
Q1.3 Hemophilia accounts for _____ of total drug costs for patients with >/=$1M in annual prescription claims.
 
Q1.4 Now that you have participated in this activity, how confident are you in your ability to engage patients with hemophilia to enhance self-monitoring and promote therapeutic adherence?
 
Q1.5 Within your plan or practice setting when applicable, how often do you plan to require and/or recommend that patients with hemophilia receive treatment from at a facility with an integrated care model such as a hemophilia treatment center (HTC), especially those individuals with inhibitors or at risk for developing inhibitors?   (1 = Never, 6 = Always)
(Please select the appropriate number on the scale below or mark if this decision or authority is outside your usual scope of practice)  
 
Evaluation Form

Medical Education Resources, Inc. is committed to excellence in continuing education, and your opinions are critical to us in this effort.  To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form.

You must complete this evaluation form to receive acknowledgment for completing this activity.
Q1.6 What is your specialty?
 
  Q1.6o. Please explain "other".
Q1.7 What best describes your primary role?
 
 
 
 
 
 
 
 
 
 
 
   
  Q1.7o. Please explain "other".
Q1.8 How many years have you been in your area of responsibility?
 
Q1.9 Approximately how many patients with hemophilia are being managed in your organization, practice setting, or affiliated organizations?
 
Q1.10 Rate how well the activity supported your achievement of these learning objectives.
           
  Describe recent insights into the safety, efficacy, and attributes of recently approved and emerging hemophilia treatment options          
  Review alignment of recently approved therapies in the current hemophilia treatment algorithm          
  Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences          
  Apply processes for managed care and specialty pharmacy professionals to improve communications and collaborations with HTCs          
Q1.11 Please select the extent to which you agree/disagree that the speakers achieved the following:
Effective in Presenting the Material
           
  Shannon Carpenter,  MD, MS          
  Edmund Pezalla, MD, MPH          
  Jeffrey Dunn, PharmD, MBA          
Q1.12 Please select the extent to which you agree/disagree that the speakers achieved the following:
Avoided Commercial Bias or Influence
           
  Shannon Carpenter,  MD, MS          
  Edmund Pezalla, MD, MPH          
  Jeffrey Dunn, PharmD, MBA          
Q1.13 Rate how well the activity achieved the following.
           
  The content was evidence based          
  The educational material provided useful information for my practice          
  The activity enhanced my current knowledge base          
  The activity provided appropriate and effective opportunities for active learning (eg, case studies, discussion, Q&A, etc)          
  The opportunities provided to assess my own learning were appropriate (eg, questions before, during or after the activity)          
Q1.14 Based upon your participation in this activity, do you intend to change your practice and/or administrative behavior?
 
 
Q1.15
Q1.16 If you plan to change your practice and/or administrative behavior, what type of changes do you plan to implement?
(check all that apply)
 
 
  Q1.16o. Please specify "other".
Q1.17 How confident are you that you will be able to make your intended changes?
 
 
Q1.18 Which of the following do you anticipate will be the primary barrier to implementing these changes?
 
 
  Q1.18o. Please specify "other".
Q1.19 Was the content of this activity fair, balanced, objective, and free of commercial bias?
 
 
  Q1.19o. Please explain.
Q1.20
Q1.21
Q1.22
Q1.23
Q1.24
Q1.25
Q1.26
Q1.27
Q1.28
Q1.29 Type of Credit
 
Q1.30
FOR PHARMACISTS: Upon submission of your evaluation you will be redirected to a web page with instructions to submit your credit to CPE Monitor.

You must follow the instructions to claim credit.

If you have any questions please email info@impactedu.net.